Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Open-label, Multicenter, Study of an Immunotherapeutic Treatment, DPX-Survivac in Combination With Low Dose Cyclophosphamide and Pembrolizumab, in Subjects With Selected Advanced and Recurrent Solid Tumours.

NCT03836352 is registered in ClinicalTrials.gov with ImmunoVaccine Technologies, Inc. (IMV Inc.) as lead sponsor.

NCT NCT03836352
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03836352 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Open-label, Multicenter, Study of an Immunotherapeutic Treatment, DPX-Survivac in Combination With Low Dose Cyclophosphamide and Pembrolizumab, in Subjects With Selected Advanced and Recurrent Solid Tumours.
Lead sponsor
ImmunoVaccine Technologies, Inc. (IMV Inc.)
Phase
Phase 2
Overall status
Active, not recruiting
Start date
December 21, 2018
Completion date
December 31, 2023
Enrollment
184 (estimated)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

bladder cancer, hepatocellular carcinoma, microsatellite instability-high, non-small cell lung cancer, ovarian cancer